tag:blogger.com,1999:blog-7857054149675424609.post5981035946423485563..comments2024-02-24T08:58:08.581+00:00Comments on RNAi Therapeutics: Silence Therapeutics to Validate Endothelial RNAi Knockdown in ManDirk Hausseckerhttp://www.blogger.com/profile/18320439857875629714noreply@blogger.comBlogger7125tag:blogger.com,1999:blog-7857054149675424609.post-12684389549805398132013-11-24T23:00:57.331+00:002013-11-24T23:00:57.331+00:00aboutface:sounds like you work for one of the othe...aboutface:sounds like you work for one of the other gene silencing companies;Silence ahs one CEO,one CSO and onbe CFO,just like all public companies and one non-exec chairman.technical staff has doubled the past 6 months and they have brought in a very well regarded CMO,a new post.They have just spent 2 hours at an investors presentation explaining the very real various strides they have and hopeAnonymousnoreply@blogger.comtag:blogger.com,1999:blog-7857054149675424609.post-83873277916033611342013-11-22T21:54:38.007+00:002013-11-22T21:54:38.007+00:00Well, peptides for targeting may be OK. Just the e...Well, peptides for targeting may be OK. Just the endothelial cell-focussed Alvos library may not be as widely applicable as once held out.Dirk Hausseckerhttps://www.blogger.com/profile/18320439857875629714noreply@blogger.comtag:blogger.com,1999:blog-7857054149675424609.post-7214798709086668662013-11-22T15:19:50.245+00:002013-11-22T15:19:50.245+00:00Dirk, thank you for the clarification. The Alvos ...Dirk, thank you for the clarification. The Alvos library seemed an important asset for targeting specific human receptors. Here is a paper from the PNAS, discussing that library and why it may be chock full of proprietary and valuable data. http://www.pnas.org/content/early/2011/10/28/1114503108.full.pdf+html?sid=82238140-3165-46e4-b1f7-4ddbc62b9658 <br /><br />Going back to the original tettrazininoreply@blogger.comtag:blogger.com,1999:blog-7857054149675424609.post-151435234300459812013-11-22T07:48:21.371+00:002013-11-22T07:48:21.371+00:00Tet, if you read my comments carefully, I believe ...Tet, if you read my comments carefully, I believe that an Alvos peptide-targeted approach and DPCs might work for endothelial cell delivery and possibly some other immediately accessible cell types.Dirk Hausseckerhttps://www.blogger.com/profile/18320439857875629714noreply@blogger.comtag:blogger.com,1999:blog-7857054149675424609.post-24693004437754591332013-11-22T03:47:32.567+00:002013-11-22T03:47:32.567+00:00Potential mismatch at Silence:
1. too many "c...Potential mismatch at Silence:<br />1. too many "chiefs"<br />2. this is going to be a financial engineering play - board is full with City/Wall Street types of software<br />3. real scientific software is relegated - expect to see insignificant scientific breakthroughsaboutfacehttps://www.blogger.com/profile/10769957742662912195noreply@blogger.comtag:blogger.com,1999:blog-7857054149675424609.post-88724158364631554352013-11-22T03:30:52.167+00:002013-11-22T03:30:52.167+00:00Dirk: "For various reasons, forcing the Alvo...Dirk: "For various reasons, forcing the Alvos peptides on the DPCs does not make sense for the company- trust me."<br /><br />Q. Can you clarify why you are pessimistic about actively targeting DPCs with peptides?<br /><br />Dirk: To give you just one technical reason: the peptides were selected as part of another large particle that would not be expected to extravasate in most tettrazininoreply@blogger.comtag:blogger.com,1999:blog-7857054149675424609.post-10407483302229638062013-11-21T21:20:59.677+00:002013-11-21T21:20:59.677+00:00redundant overhang. overdue decision
cheersredundant overhang. overdue decision<br />cheersAnonymousnoreply@blogger.com